2021
Association between percentage of positive biopsy cores and risk of pelvic lymph node involvement in prostate cancer.
Yang D, Dee E, Arega M, Nguyen P, Orio P, King M, Kann B, Yu J, Cook K, Ma T, Kishan A, Muralidhar V. Association between percentage of positive biopsy cores and risk of pelvic lymph node involvement in prostate cancer. Journal Of Clinical Oncology 2021, 39: 205-205. DOI: 10.1200/jco.2021.39.6_suppl.205.Peer-Reviewed Original ResearchPercentage of positive biopsy coresRisk of pelvic lymph node involvementPelvic lymph node involvementLymph node involvementPositive biopsy coresPelvic lymph nodesProstate cancerRadical prostatectomyBiopsy coresNode involvementLymph nodesDefinitive treatment of prostate cancerGleason 9-10 diseasePositive pelvic lymph nodesTreatment of prostate cancerBiopsy Gleason scoreClinicopathological prognostic variablesElective nodal irradiationGleason 8 diseasePathologic nodal evaluationClinical tumor stageNational Cancer DatabaseTime of RPClinically relevant associationMultivariate logistic regression
2019
Prostatectomy in men with clinically positive lymph nodes.
Ghali F, Ryan S, Hansen M, Hayn M, Sammon J, Sarkar R, Murphy J, Kader A, Rose B. Prostatectomy in men with clinically positive lymph nodes. Journal Of Clinical Oncology 2019, 37: 327-327. DOI: 10.1200/jco.2019.37.7_suppl.327.Peer-Reviewed Original ResearchCox proportional hazards modelPositive lymph nodesBiopsy Gleason scoreProportional hazards modelProstate cancerLymph nodesPCa patientsGleason scoreHazards modelClinical positive lymph nodesHigh-risk prostate cancerNational Cancer DatabaseRisk prostate cancerPrimary treatment modalityPositive surgical marginsPathologic T stageDifficult clinical scenariosMedian followWorse OSNodal statusRisk patientsSystemic therapyClinical stagingSurgical marginsT stage
2014
Comparing 3-T multiparametric MRI and the Partin tables to predict organ-confined prostate cancer after radical prostatectomy
Gupta RT, Faridi KF, Singh AA, Passoni NM, Garcia-Reyes K, Madden JF, Polascik TJ. Comparing 3-T multiparametric MRI and the Partin tables to predict organ-confined prostate cancer after radical prostatectomy. Urologic Oncology Seminars And Original Investigations 2014, 32: 1292-1299. PMID: 24863013, DOI: 10.1016/j.urolonc.2014.04.017.Peer-Reviewed Original ResearchConceptsNegative predictive valuePositive predictive valueOrgan-confined prostate cancerExtracapsular extensionOC diseasePartin tablesRadical prostatectomyClinical stageProstate cancerPredictive valueMedian prostate-specific antigen levelProstate-specific antigen levelMultiparametric magnetic resonance imagingHigh negative predictive valueHigh positive predictive valueBiopsy Gleason scoreInstitutional review board approvalAvailable clinical parametersDigital rectal examinationSeminal vesicle invasionHigher prognostic accuracyProstate cancer treatmentReview board approvalMagnetic resonance imagingLogistic regression models
2011
Inherited Variants in the Chemokine CCL2 Gene and Prostate Cancer Aggressiveness in a Caucasian Cohort
Sun T, Mary L, Oh W, Freedman M, Pomerantz M, Pienta K, Kantoff P. Inherited Variants in the Chemokine CCL2 Gene and Prostate Cancer Aggressiveness in a Caucasian Cohort. Clinical Cancer Research 2011, 17: 1546-1552. PMID: 21135144, PMCID: PMC3060307, DOI: 10.1158/1078-0432.ccr-10-2015.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAllelesChemokine CCL2Cohort StudiesDisease ProgressionGenetic Predisposition to DiseaseGenetic VariationGenotypeHaplotypesHumansLinkage DisequilibriumMaleMiddle AgedNeoplasm InvasivenessNeoplasm MetastasisPolymorphism, Single NucleotideProstatectomyProstatic NeoplasmsRiskConceptsC-C chemokine ligand 2Prostate cancer aggressivenessSingle nucleotide polymorphismsCancer aggressivenessMarkers of disease aggressivenessAssociated with advanced pathological stageBiopsy Gleason scoreGood-risk featuresProstate cancer developmentProstate cancer progressionAdvanced pathological stageChemokine ligand 2Associated with markersProstate cancer tumorigenesisGleason scoreRadical prostatectomyClinicopathological variablesPathological stageDisease aggressivenessPatient cohortG alleleGermline variantsCaucasian cohortProstateRisk features
2009
PP138 A whole blood RNA transcript-based model to predict biopsy Gleason score in newly diagnosed prostate cancer patients
Oh W, Magidson J, Bankaitis-Davis D, Siconolfi L, Schurko B, Cantu R, Braitsch S, Wassman K, Kantoff P, Ross R. PP138 A whole blood RNA transcript-based model to predict biopsy Gleason score in newly diagnosed prostate cancer patients. European Journal Of Cancer Supplements 2009, 7: 27. DOI: 10.1016/s1359-6349(09)72197-4.Peer-Reviewed Original Research
2008
Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer
Ross R, Xie W, Regan M, Pomerantz M, Nakabayashi M, Daskivich T, Sartor O, Taplin M, Kantoff P, Oh W. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer. Cancer 2008, 112: 1247-1253. PMID: 18293426, DOI: 10.1002/cncr.23304.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAndrogen AntagonistsCohort StudiesDisease ProgressionFollow-Up StudiesGonadotropin-Releasing HormoneHumansMaleMiddle AgedNeoplasm StagingNeoplasms, Hormone-DependentOrchiectomyProstate-Specific AntigenProstatectomyProstatic NeoplasmsRetrospective StudiesSurvival RateConceptsEfficacy of androgen deprivation therapyAndrogen deprivation therapy initiationAndrogen deprivation therapyProstate-specific antigenHormone-sensitive prostate cancerProstate cancerGleason scoreDeprivation therapyM+ patientsLower serum prostate-specific antigenUse of androgen deprivation therapyCohort of prostate cancer patientsLower biopsy Gleason scoreSerum prostate-specific antigenMetastatic disease statusBiopsy Gleason scoreAdvanced prostate cancerAbsence of metastasesProstate cancer patientsShortened TTPMedian TTPLocal therapyDecreased TTPM patientsRetrospective study
2006
Development of an Integrated Prostate Cancer Research Information System
Oh W, Hayes J, Evan C, Manola J, George D, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright R, Tormey L, Talcott J, Rubin M, Loda M, Sellers W, Richie J, Kantoff P, Weeks J. Development of an Integrated Prostate Cancer Research Information System. Clinical Genitourinary Cancer 2006, 5: 61-66. PMID: 16859581, DOI: 10.3816/cgc.2006.n.019.Peer-Reviewed Original ResearchConceptsMedian prostate-specific antigen levelIncreasing prostate-specific antigenProstate-specific antigen levelClinical databaseBiopsy Gleason scoreProstate cancer databaseProstate-specific antigenAge of patientsCollection of clinical dataT2 diseaseGleason scoreAntigen levelsProstate cancerCancer DatabaseClinical dataLevel of concordanceCancer CenterPatientsMedical recordsProstateOutcome dataClinical research information systemResearch Information SystemTrigger symptomsClinical care
2005
Neoadjuvant Docetaxel before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer
Febbo P, Richie J, George D, Loda M, Manola J, Shankar S, Barnes A, Tempany C, Catalona W, Kantoff P, Oh W. Neoadjuvant Docetaxel before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer. Clinical Cancer Research 2005, 11: 5233-5240. PMID: 16033841, DOI: 10.1158/1078-0432.ccr-05-0299.Peer-Reviewed Original ResearchConceptsEndorectal magnetic resonance imagingHigh-risk localized prostate cancerProstate-specific antigen declinePathological complete responseLocalized prostate cancerMagnetic resonance imagingRadical prostatectomyNeoadjuvant docetaxelComplete responseProstate cancerSerum prostate-specific antigen measurementSerum prostate-specific antigen levelClinical stage T3 diseaseMaximum tumor volume reductionNo pathologic complete responsesProstate-specific antigen levelProstate-specific antigen measurementNeoadjuvant docetaxel chemotherapyStage T3 diseaseBiopsy Gleason scoreTumor volume reductionProstate-specific antigenResponse to chemotherapyDecreased tumor volumeFrozen tumor specimens
2003
The Evolving Role of Chemotherapy and Other Systemic Therapies for Managing Localized Prostate Cancer
Oh W. The Evolving Role of Chemotherapy and Other Systemic Therapies for Managing Localized Prostate Cancer. Journal Of Urology 2003, 170: s28-s34. PMID: 14610407, DOI: 10.1097/01.ju.0000095356.02647.64.Peer-Reviewed Original ResearchConceptsLocalized prostate cancerProstate cancerSystemic therapyLocalized diseaseClinical trialsClinical stage T3 diseaseHigh-risk localized diseaseSerum prostate specific antigenHormone refractory prostate cancerHigh riskBiopsy Gleason scoreStage T3 diseaseStudies evaluating chemotherapyRefractory prostate cancerAdvanced prostate cancerMolecular targeted agentsProstate specific antigenMedline literature reviewNeoadjuvant settingGleason scoreT3 diseaseMetastatic diseaseCytotoxic chemotherapyLocal therapyAdjuvant chemotherapyNeoadjuvant therapy for high-risk localized prostate cancer
Yu E, Oh W. Neoadjuvant therapy for high-risk localized prostate cancer. Current Oncology Reports 2003, 5: 250-257. PMID: 12667424, DOI: 10.1007/s11912-003-0118-3.Peer-Reviewed Original ResearchConceptsHigh-risk localized prostate cancerLocalized prostate cancerProstate cancerSerum prostate-specific antigen levelClinical stage T3 diseaseProstate-specific antigen levelHormone-refractory prostate cancerBiopsy Gleason scoreNeoadjuvant hormonal manipulationStage T3 diseaseLocally advanced diseaseMolecular targeted agentsProstate cancer patientsRisk of recurrenceGleason scoreNeoadjuvant settingNeoadjuvant therapyT3 diseaseMetastatic diseaseLocal therapyHormone therapyPalliative benefitSurvival benefitAdvanced diseaseAntigen levels
2001
Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report
Oh W, George D, Kaufman D, Moss K, Smith M, Richie J, Kantoff P. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report. Seminars In Oncology 2001, 28: 40-44. PMID: 11685727, DOI: 10.1016/s0093-7754(01)90153-8.Peer-Reviewed Original ResearchConceptsHigh-risk localized prostate cancerLocalized prostate cancerProstate specific antigenProstate cancerRadical prostatectomyClinical stage T3 diseaseProstate specific antigen measurementsPathologic complete response rateHormone-refractory prostate cancerOutcomes of radical prostatectomyEndorectal magnetic resonance imagingBiopsy Gleason scoreStage T3 diseaseComplete response rateDigital rectal examinationEffective treatment optionMagnetic resonance imagingWeekly docetaxelDocetaxel chemotherapyGleason scoreNeoadjuvant docetaxelT3 diseaseSystemic therapyRectal examinationSpecific antigen
1999
Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients
Lee N, Newhouse J, Olsson C, Benson M, Petrylak D, Schiff P, Bagiella E, Malyszko B, Ennis R. Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients. Urology 1999, 54: 490-494. PMID: 10475360, DOI: 10.1016/s0090-4295(99)00150-8.Peer-Reviewed Original ResearchConceptsPositive CT scanGleason scoreComputed tomography scanCT scanClinical stageProstate cancerIndependent predictorsTomography scanSerum prostate-specific antigen levelProstate-specific antigen levelClinical stage T2bLow-risk patientsBiopsy Gleason scoreGleason score 8Negative CT scanAbdominopelvic CT scansGleason score 2Low-risk groupSignificant independent predictorsProstate cancer biopsiesStage T2bPathologic reviewStaging evaluationPositive CTAntigen levels
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply